Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-03-04
2010-06-22
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S256000, C514S318000, C544S333000, C546S194000, C546S200000
Reexamination Certificate
active
07741342
ABSTRACT:
Thalidomide derivative (I) and their bases or salts are new: where R represents CHR1NR2R3, CHR1NR4C(O)CHR5NR2R3, W or CHR5NR4C(O)W, where R1, R4and R5represent independently each other H, C1-4alkyl, R2is a C1-4alkyl, R3is a C1-4alkyl, or R2and R3together represents 1,3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, W represents 4-, 5-, 6-, 7-, or 8-mumbered, saturated or unsaturated heterocycle. The invention also relates to processes of production thereof and the use of thereof as an active pharmaceutical ingredient.
REFERENCES:
patent: 2008/0051432 (2008-02-01), Zhang
Schneider et al. “Acylated N-hydroxymethylthalidomide . . . ” CA 127:331403 (1997).
“Derivative” Dictionary (2009) (from internet).
Bundgaard “Design of prodrugs” p. 8 (1985).
Zhang et al. “Preparation of water . . . ” CA 141:295871 (2004).
Wadler “Thalidomide for advaced . . . ” Am. Cancer Soc. v.103(1)p. 1-4 (2004).
Chang Celia
Che Fengsheng
Matthias Scholl P.C.
Scholl Matthias
Zhang Hesheng
LandOfFree
Water-soluble thalidomine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Water-soluble thalidomine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Water-soluble thalidomine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4247608